Phenotype expression in women with CMT1X
暂无分享,去创建一个
Mary M Reilly | Carly E Siskind | Sinéad M Murphy | Richard Ovens | James Polke | Michael E Shy | M. Shy | C. Siskind | J. Polke | M. Reilly | S. Murphy | R. Ovens
[1] A. Brice,et al. Clinical, electrophysiological and molecular genetic characteristics of 93 patients with X-linked Charcot-Marie-Tooth disease. , 2001, Brain : a journal of neurology.
[2] K. Ørstavik. X chromosome inactivation in clinical practice , 2009, Human Genetics.
[3] M. Shy,et al. Charcot‐marie‐tooth disease subtypes and genetic testing strategies , 2011, Annals of neurology.
[4] S. Scherer,et al. CMT1X phenotypes represent loss of GJB1 gene function , 2007, Neurology.
[5] K. Fischbeck,et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. , 1993, Science.
[6] Skewed X inactivation in healthy individuals and in different diseases , 2006 .
[7] C. Stoll,et al. SIMPLE mutation analysis in dominant demyelinating Charcot‐Marie‐Tooth disease: three novel mutations , 2006, Journal of the peripheral nervous system : JPNS.
[8] K. Ørstavik. Skewed X inactivation in healthy individuals and in different diseases. , 2006, Acta paediatrica (Oslo, Norway : 1992). Supplement.
[9] A. Sharp,et al. Age- and tissue-specific variation of X chromosome inactivation ratios in normal women , 2000, Human Genetics.
[10] J. Lupski,et al. Practice Parameter: Evaluation of distal symmetric polyneuropathy: Role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review) , 2009, Neurology.
[11] Jun Yu Li,et al. Reliability and validity of the CMT neuropathy score as a measure of disability , 2005, Neurology.
[12] D. Linch,et al. Tissue specificity of X-chromosome inactivation patterns. , 1994, Blood.
[13] W. Brown,et al. Genotype/phenotype correlations in X-linked dominant Charcot-Marie-Tooth disease. , 1999, Annals of the New York Academy of Sciences.
[14] K. Fischbeck,et al. A Unique Mutation in Connexin32 Associated with Severe, Early Onset CMTX in a Heterozygous Female , 1999, Annals of the New York Academy of Sciences.
[15] H. Willard,et al. X chromosome-inactivation patterns of 1,005 phenotypically unaffected females. , 2006, American journal of human genetics.
[16] J. Lupski,et al. Practice Parameter: Evaluation of distal symmetric polyneuropathy: Role of laboratory and genetic testing (an evidence-based review) , 2009, Neurology.
[17] X. Estivill,et al. Estimation of the Mutation Frequencies in Charcot-Marie-Tooth Disease Type 1 and Hereditary Neuropathy with Liability to Pressure Palsies: A European Collaborative Study , 1996, European journal of human genetics : EJHG.
[18] M. Leppert,et al. Heritability of X chromosome--inactivation phenotype in a large family. , 1996, American journal of human genetics.
[19] H. Zoghbi,et al. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. , 1992, American journal of human genetics.
[20] J. Belmont. Genetic control of X inactivation and processes leading to X-inactivation skewing. , 1996, American journal of human genetics.
[21] K. Arimura,et al. Clinical phenotype in X-linked Charcot-Marie-Tooth disease with an entire deletion of the connexin 32 coding sequence , 2001, Journal of the Neurological Sciences.